| Primary information |
|---|
| sequence ID | Seq_7146 |
| Peptide sequence | SGPRRYTIAALLSPYSYSTTAVVTNPKE |
| CancerPDF_ID | CancerPDF_ID8647, CancerPDF_ID9913, |
| PMID | 19674866,21533267 |
| Protein Name | Transthretin ( Cterminal fragment of protein TTHY),Transthyretin |
| UniprotKB Entry Name | TTHY_HUMAN,TTHY_HUMAN |
| Fluid | Cerbrospinal fluid,Serum |
| M/Z | NA,761.42 |
| Charge | 1,4 |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS |
| Peptide Identification technique | nanoESI-qTOF-MS/MS,LC/MS/MS |
| Quantification Technique | Q/TOF/MS,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,1.49 |
| CancerPDF_ID | CancerPDF_ID8647, CancerPDF_ID9913, |
| p-Value | 0.05,NA |
| Software | MASCOT,MASCOT |
| Length | 28,28 |
| Cancer Type | Glioblastoma (Malignant brain tumor),Lung adenocarcinoma |
| Database | SwissProt Database and MSDB.,Swissprot Database (57.4) |
| Modification | NA,NA |
| Number of Patients | 11 patient with glioblastoma,62 lung adenocarcinoma and 30 healthy control |
| Regulation | Upregulated in cancer as compare to normal control,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |